Longo Caterina

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The introduction of a newly developed target therapy for metastatic melanomas poses the challenge to have a good molecular stratification of those patients who may benefit from this therapeutic option. Practically, BRAF mutation status (V600E) is commonly screened although other non-V600E mutations (i.e., K-R-M-D) could be found in some patients who respond(More)
  • 1